ANDA 71291, held by Hospira. Metoclopramide Hydrochloride.
As of Nov 21, 2026, ANDA 71291 (Metoclopramide Hydrochloride), held by Hospira, was first approved by FDA on Mar 3, 1989, with 9 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Mar 3, 1989 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Metoclopramide HydrochlorideEQ 5MG BASE/ML · injectable;injection | Metoclopramide Hydrochloride | Discontinued |
| Nov 20, 2007 | Supplement 10Labeling | Approved | None posted |
| Sep 17, 2001 | Supplement 8Manufacturing | Approved | None posted |
| Oct 5, 2000 | Supplement 7Labeling | Approved | None posted |
| Sep 13, 1999 | Supplement 6Labeling | Approved | None posted |
| Jun 8, 1999 | Supplement 5Labeling | Approved | None posted |
| May 13, 1998 | Supplement 4Labeling | Approved | None posted |
| Aug 7, 1995 | Supplement 3Labeling | Approved | None posted |
| Jan 27, 1995 | Supplement 2Manufacturing | Approved | None posted |
| Jun 22, 1993 | Supplement 1Labeling | Approved | None posted |
| Mar 3, 1989 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. “What FDA's review says” is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters